<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575717</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 11-1149</org_study_id>
    <secondary_id>IF# 1333386</secondary_id>
    <secondary_id>HS#: 11-02021</secondary_id>
    <nct_id>NCT01575717</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List</brief_title>
  <official_title>The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Branch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of two different doses of vitamin D3
      (2000 IU vs. 4000 IU) on serum 25-hydroxyvitamin D (25OHD) levels in patients with
      hepatocellular carcinoma on the liver transplant list. The study will help determine the dose
      of vitamin D3 that is required for patients with liver cancer to reach a normal level of
      25OHD in the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants will be identified from Mount Sinai Hospital's active liver transplant
      list. The hepatologists at Mount Sinai's Transplant Institute will ask each potential
      participant if she/he is interested in participating. If the patient expresses an interest in
      the study, one of the researchers will meet with the patient when the patient is at Mount
      Sinai for a regular appointment and will describe the study to the potential participant. If
      a patient continues to be interested in participating, she/he will be given a copy of the
      IRB-approved consent document to read. The consent document will be used as a guide for
      explaining the study in detail to the patient. If the patient's preferred language is
      Spanish, she/he will be given a consent document in Spanish and the study will be explained
      in Spanish.

      Once the subject's 25(OH)D level is known, if the subject's 25(OH)D level is ≤ 15 ng/ml, the
      participant will be contacted by one of the investigators on the research team and instructed
      to begin taking 2 tablets per day (4000 IU total) of vitamin D. If the subject's 25(OH)D
      level is greater than 15 and ≤ 25, the participant will be contacted by one of the
      investigators on the research team and told to begin taking 1 tablet (2000 IU total) per day
      of vitamin D. If the participant's vitamin D level is &lt; 25 ng/ml, they are considered Vitamin
      D insufficient/deficient. If the Serum Vitamin D is &gt; 25 ng/ml they will be informed that
      they are not to take any vitamin D and they will be followed as controls for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum levels of 25-hydroxyvitamin D</measure>
    <time_frame>at baseline, and at 3 and 6 months</time_frame>
    <description>Change in serum levels of 25-hydroxyvitamin D at 3 months and 6 months compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of liver enzymes (ALT, AST and Alk phos)</measure>
    <time_frame>at baseline, and at 3 and 6 months</time_frame>
    <description>Change in serum levels of liver enzymes (ALT, AST and Alk phos) at 3 months and at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>at baseline, and at 3 and 6 months</time_frame>
    <description>Change in serum creatinine at 3 months and at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation profile (PT/PTT and INR)</measure>
    <time_frame>at baseline, and at 3 and 6 months</time_frame>
    <description>Change in coagulation profile (PT/PTT and INR) at 3 months and at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Model for End stage Liver Disease score (MELD)</measure>
    <time_frame>at baseline, and at 3 and 6 months</time_frame>
    <description>Change in Model for End stage Liver Disease score (MELD) at 3 months and at 6 months compared to baseline.
Calculated using the following formula: Meld = 10x ((0.957 x Ln(creatinine mg/dl)) + (0.378 x Ln(bilirubin mg/dl)) + (1.120 x Ln(INR)) + 0.643)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vitamin D 4000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 4000 IU of vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 2000IU of vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 4000 IU</intervention_name>
    <description>Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months</description>
    <arm_group_label>Vitamin D 4000</arm_group_label>
    <other_name>Vitamin D 4000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 2000 IU</intervention_name>
    <description>Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months</description>
    <arm_group_label>Vitamin D 2000</arm_group_label>
    <other_name>Vitamin D 2000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 years and older)

          -  Diagnosis of hepatocellular carcinoma

          -  On the list awaiting liver transplantation

          -  Able to give informed consent

          -  Expected to receive care following liver transplantation at the Mount Sinai School of
             Medicine

          -  Any race/ethnicity/socioeconomic status

        Exclusion Criteria:

          -  Pediatric patient (less than 18 years of age)

          -  Unable to give informed consent

          -  Untreated primary hyperparathyroidism (ICD9 codes 252.01XX and 252.00XX)

          -  Untreated hypercalcemia (serum calcium level &gt; 11 mg/dl; ICD9 codes 275.42XX, 259.3XX,
             252.00F)

          -  Pregnancy (will be determined by asking the patient and reviewing the medical record)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea D Branch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea D Branch, PhD</last_name>
    <phone>212-659-8371</phone>
    <email>andrea.branch@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea D Branch, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Malham M, Jørgensen SP, Ott P, Agnholt J, Vilstrup H, Borre M, Dahlerup JF. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol. 2011 Feb 21;17(7):922-5. doi: 10.3748/wjg.v17.i7.922.</citation>
    <PMID>21412501</PMID>
  </reference>
  <reference>
    <citation>Wibaux C, Legroux-Gerot I, Dharancy S, Boleslawski E, Declerck N, Canva V, Mathurin P, Pruvot FR, Cortet B. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine. 2011 Jul;78(4):387-91. doi: 10.1016/j.jbspin.2011.03.001. Epub 2011 May 11.</citation>
    <PMID>21565541</PMID>
  </reference>
  <reference>
    <citation>Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010 Sep;55(9):2624-8. doi: 10.1007/s10620-009-1069-9. Epub 2009 Dec 4.</citation>
    <PMID>19960254</PMID>
  </reference>
  <reference>
    <citation>Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001 Dec;69(6):321-6.</citation>
    <PMID>11800228</PMID>
  </reference>
  <reference>
    <citation>Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, Di Menna S, Pirazzi C, Corradini SG, Mennini G, Rossi M, Berloco P, Merli M. Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc. 2010 May;42(4):1191-3. doi: 10.1016/j.transproceed.2010.03.096.</citation>
    <PMID>20534258</PMID>
  </reference>
  <reference>
    <citation>Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, Cussigh A, Occhino G, Baccarani U, Pirisi M, Toniutto P. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int. 2010 Mar;30(3):417-44. doi: 10.1111/j.1478-3231.2009.02154.x. Epub 2009 Oct 22.</citation>
    <PMID>19849776</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Andrea Branch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>liver neoplasms</keyword>
  <keyword>liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 6, 2017</submitted>
    <returned>May 15, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

